Positional proteomics in the era of the human proteome project on the doorstep of precision medicine

Biochimie

Volumn 122, Issue , 2016, Pages 110-118

  Eckhard, Ulrich ^a   Marino, Giada ^a   Butler, Georgina S ^a   Overall, Christopher M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

COFRADIC; Degradomics; Human proteome project (HPP); Limited proteolysis; Positional proteomics; Precision medicine; Proteolytic processing; TAILS N Terminomics

Indexed keywords

BIOLOGICAL MARKER; PROTEINASE INHIBITOR; PROTEOME; SIGNAL PEPTIDE; PEPTIDE; PEPTIDE HYDROLASE;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; COMBINED FRACTIONAL DIAGONAL CHROMATOGRAPHY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN PROTEOME PROJECT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; TERMINAL AMINE ISOTOPIC LABELING OF SUBSTRATES; WELLBEING; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM; PROCEDURES; PROTEIN DEGRADATION; TRENDS;

BIOMARKERS; HUMANS; PEPTIDE HYDROLASES; PEPTIDES; PRECISION MEDICINE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PROTEOME; PROTEOMICS; SUBSTRATE SPECIFICITY;

EID: 84957805102     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2015.10.018     Document Type: Review

References (81)

1. J.D. McPherson, M. Marra, L. Hillier, R.H. Waterston, A. Chinwalla, J. Wallis, and et al. A physical map of the human genome Nature 409 2001 934 941 10.1038/35057157
2. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome Nature 431 2004 931 945 10.1038/nature03001
3. G.S. Omenn The strategy, organization, and progress of the HUPO human proteome project J. Proteom. 100 2014 3 7 10.1016/j.jprot.2013.10.012
4. L.M. Smith, and N.L. Kelleher Proteoform: a single term describing protein complexity Nat. Methods 10 2013 186 187 10.1038/nmeth.2369
5. R. Aebersold, G.D. Bader, A.M. Edwards, J.E. van Eyk, M. Kussmann, J. Qin, and et al. The biology/disease-driven human proteome project (B/D-HPP): enabling protein research for the life sciences community J. Proteom. Res. 12 2013 23 27 10.1021/pr301151m
6. E.W. Deutsch, H. Lam, and R. Aebersold PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows EMBO Rep. 9 2008 429 434 10.1038/embor.2008.56
7. F. Desiere, E.W. Deutsch, N.L. King, A.I. Nesvizhskii, P. Mallick, J. Eng, and et al. The PeptideAtlas project Nucleic Acids Res. 34 2006 D655 D658 10.1093/nar/gkj040
8. M. Uhlén, E. Björling, C. Agaton, C.A.-K. Szigyarto, B. Amini, E. Andersen, and et al. A human protein atlas for normal and cancer tissues based on antibody proteomics Mol. Cell. Proteom. MCP 4 2005 1920 1932 10.1074/mcp.M500279-MCP200
9. M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, and et al. Proteomics. Tissue-based map of the human proteome Science 347 2015 1260419 10.1126/science.1260419
10. M.-S. Kim, S.M. Pinto, D. Getnet, R.S. Nirujogi, S.S. Manda, R. Chaerkady, and et al. A draft map of the human proteome Nature 509 2014 575 581 10.1038/nature13302
11. M. Wilhelm, J. Schlegl, H. Hahne, A. Moghaddas Gholami, M. Lieberenz, M.M. Savitski, and et al. Mass-spectrometry-based draft of the human proteome Nature 509 2014 582 587 10.1038/nature13319
12. P. Gaudet, P.-A. Michel, M. Zahn-Zabal, I. Cusin, P.D. Duek, O. Evalet, and et al. The neXtProt knowledgebase on human proteins: current status Nucleic Acids Res. 43 2015 D764 D770 10.1093/nar/gku1178
13. S. Beck, A. Michalski, O. Raether, M. Lubeck, S. Kaspar, N. Goedecke, and et al. The Impact II, a very high-resolution quadrupole time-of-flight instrument (QTOF) for deep shotgun proteomics Mol. Cell. Proteom. MCP 14 2015 2014 2029 10.1074/mcp.M114.047407
14. A.M. Brunner, P. Lössl, F. Liu, R. Huguet, C. Mullen, M. Yamashita, and et al. Benchmarking multiple fragmentation methods on an orbitrap fusion for top-down phospho-proteoform characterization Anal. Chem. 87 2015 4152 4158 10.1021/acs.analchem.5b00162
15. N.L. Anderson, and N.G. Anderson The human plasma proteome: history, character, and diagnostic prospects Mol. Cell. Proteom. MCP 1 2002 845 867
16. S. Faulkner, G. Elia, M. Hillard, P. O'Boyle, M. Dunn, and D. Morris Immunodepletion of albumin and immunoglobulin G from bovine plasma Proteomics 11 2011 2329 2335 10.1002/pmic.201000364
17. E. Boschetti, and P.G. Righetti The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species J. Proteom. 71 2008 255 264 10.1016/j.jprot.2008.05.002
18. T. Nilsson, M. Mann, R. Aebersold, J.R. Yates, A. Bairoch, and J.J.M. Bergeron Mass spectrometry in high-throughput proteomics: ready for the big time Nat. Methods 7 2010 681 685 10.1038/nmeth0910-681
19. A.I. Nesvizhskii, and R. Aebersold Interpretation of shotgun proteomic data: the protein inference problem Mol. Cell. Proteom. MCP 4 2005 1419 1440 10.1074/mcp.R500012-MCP200
20. P.F. Lange, P.F. Huesgen, K. Nguyen, and C.M. Overall Annotating N termini for the human proteome project: N termini and Nα-acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome J. Proteom. Res. 13 2014 2028 2044 10.1021/pr401191w
21. A. Prudova, K. Serrano, U. Eckhard, N. Fortelny, D.V. Devine, and C.M. Overall TAILS N-terminomics of human platelets reveals pervasive metalloproteinase-dependent proteolytic processing in storage Blood 124 2014 e49 e60 10.1182/blood-2014-04-569640
22. U. Eckhard, G. Marino, S.R. Abbey, G. Tharmarajah, I. Matthew, and C.M. Overall The human dental pulp proteome and N-terminome: levering the unexplored potential of semitryptic peptides enriched by TAILS to identify missing proteins in the human proteome project in underexplored tissues J. Proteom. Res. 2015 10.1021/acs.jproteome.5b00579
23. K. Gevaert, M. Goethals, L. Martens, J. Van Damme, A. Staes, G.R. Thomas, and et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides Nat. Biotechnol. 21 2003 566 569 10.1038/nbt810
24. S.-H. Chen, C.-R. Chen, S.-H. Chen, D.-T. Li, and J.-L. Hsu Improved N(α)-acetylated peptide enrichment following dimethyl labeling and SCX J. Proteom. Res. 12 2013 3277 3287 10.1021/pr400127j
25. A.S. Venne, F.A. Solari, F. Faden, T. Paretti, N. Dissmeyer, and R.P. Zahedi An improved workflow for quantitative N-terminal charge-based fractional diagonal chromatography (ChaFRADIC) to study proteolytic events in Arabidopsis thaliana Proteomics 2015 10.1002/pmic.201500014
26. O. Kleifeld, A. Doucet, U. auf dem Keller, A. Prudova, O. Schilling, R.K. Kainthan, and et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products Nat. Biotechnol. 28 2010 281 288 10.1038/nbt.1611
27. A. Prudova, U. auf dem Keller, G.S. Butler, and C.M. Overall Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics Mol. Cell. Proteom. MCP 9 2010 894 911 10.1074/mcp.M000050-MCP201
28. N. Fortelny, J.H. Cox, R. Kappelhoff, A.E. Starr, P.F. Lange, P. Pavlidis, and et al. Network analyses reveal pervasive functional regulation between proteases in the human protease web PLoS Biol. 12 2014 e1001869 10.1371/journal.pbio.1001869
29. U. auf dem Keller, A. Prudova, U. Eckhard, B. Fingleton, and C.M. Overall Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation Sci. Signal 6 2013 rs2 10.1126/scisignal.2003512
30. C.L. Bellac, A. Dufour, M.J. Krisinger, A. Loonchanta, A.E. Starr, U. Auf dem Keller, and et al. Macrophage matrix metalloproteinase-12 dampens inflammation and neutrophil influx in arthritis Cell Rep. 9 2014 618 632 10.1016/j.celrep.2014.09.006
31. O. Kleifeld, A. Doucet, A. Prudova, U. auf dem Keller, M. Gioia, J.N. Kizhakkedathu, and et al. Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates Nat. Protoc. 6 2011 1578 1611 10.1038/nprot.2011.382
32. A.S. Venne, F.-N. Vögtle, C. Meisinger, A. Sickmann, and R.P. Zahedi Novel highly sensitive, specific, and straightforward strategy for comprehensive N-terminal proteomics reveals unknown substrates of the mitochondrial peptidase Icp55 J. Proteom. Res. 12 2013 3823 3830 10.1021/pr400435d
33. Z.W. Lai, A. Gomez-Auli, E.J. Keller, B. Mayer, M.L. Biniossek, and O. Schilling Enrichment of protein N-termini by charge reversal of internal peptides Proteomics 2015 10.1002/pmic.201500023
34. G. Xu, S.B.Y. Shin, and S.R. Jaffrey Global profiling of protease cleavage sites by chemoselective labeling of protein N-termini Proc. Natl. Acad. Sci. U. S. A. 106 2009 19310 19315 10.1073/pnas.0908958106
35. H.A.I. Yoshihara, S. Mahrus, and J.A. Wells Tags for labeling protein N-termini with subtiligase for proteomics Bioorg. Med. Chem. Lett. 18 2008 6000 6003 10.1016/j.bmcl.2008.08.044
36. L.D. Rogers, and C.M. Overall Proteolytic post-translational modification of proteins: proteomic tools and methodology Mol. Cell. Proteom. MCP 12 2013 3532 3542 10.1074/mcp.M113.031310
37. G. Marino, U. Eckhard, C.M. Overall, Protein Termini, and Their Modifications Revealed by positional proteomics ACS Chem. Biol. 2015 10.1021/acschembio.5b00189
38. P.F. Huesgen, and C.M. Overall N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification Physiol. Plant 145 2012 5 17 10.1111/j.1399-3054.2011.01536.x
39. K. Plasman, P. Van Damme, and K. Gevaert Contemporary positional proteomics strategies to study protein processing Curr. Opin. Chem. Biol. 17 2013 66 72 10.1016/j.cbpa.2012.11.026
40. O. Schilling, O. Barré, P.F. Huesgen, and C.M. Overall Proteome-wide analysis of protein carboxy termini: C terminomics Nat. Methods 7 2010 508 511 10.1038/nmeth.1467
41. P. Van Damme, A. Staes, S. Bronsoms, K. Helsens, N. Colaert, E. Timmerman, and et al. Complementary positional proteomics for screening substrates of endo- and exoproteases Nat. Methods 7 2010 512 515 10.1038/nmeth.1469
42. S. Tanco, K. Gevaert, and P. Van Damme C-terminomics: targeted analysis of natural and posttranslationally modified protein and peptide C-termini Proteomics 15 2015 903 914 10.1002/pmic.201400301
43. P.F. Huesgen, P.F. Lange, L.D. Rogers, N. Solis, U. Eckhard, O. Kleifeld, and et al. LysargiNase mirrors trypsin for protein C-terminal and methylation-site identification Nat. Methods 12 2015 55 58 10.1038/nmeth.3177
44. C. López-Otín, and C.M. Overall Protease degradomics: a new challenge for proteomics Nat. Rev. Mol. Cell Biol. 3 2002 509 519 10.1038/nrm858
45. E. Dall, J.C. Fegg, P. Briza, and H. Brandstetter Structure and mechanism of an aspartimide-dependent peptide ligase in human legumain Angew. Chem. Int. Ed. Engl. 54 2015 2917 2921 10.1002/anie.201409135
46. H. Nagase, R. Visse, and G. Murphy Structure and function of matrix metalloproteinases and TIMPs Cardiovasc. Res. 69 2006 562 573 10.1016/j.cardiores.2005.12.002
47. G. Murphy, and H. Nagase Progress in matrix metalloproteinase research Mol. Asp. Med. 29 2008 290 308 10.1016/j.mam.2008.05.002
48. A.M. Tester, J.H. Cox, A.R. Connor, A.E. Starr, R.A. Dean, X.S. Puente, and et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity PLoS One 2 2007 e312 10.1371/journal.pone.0000312
49. H. Nagase Cell surface activation of progelatinase A (proMMP-2) and cell migration Cell Res. 8 1998 179 186 10.1038/cr.1998.18
50. B. Steffensen, H.F. Bigg, and C.M. Overall The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation J. Biol. Chem. 273 1998 20622 20628
51. A. Dufour, and C.M. Overall Missing the target: matrix metalloproteinase antitargets in inflammation and cancer Trends Pharmacol. Sci. 34 2013 233 242 10.1016/j.tips.2013.02.004
52. P.F. Huesgen, P.F. Lange, and C.M. Overall Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease Proteom. Clin. Appl. 8 2014 338 350 10.1002/prca.201300104
53. C.E. Parker, and C.H. Borchers Mass spectrometry based biomarker discovery, verification, and validation-quality assurance and control of protein biomarker assays Mol. Oncol. 8 2014 840 858 10.1016/j.molonc.2014.03.006
54. A. Doucet, G.S. Butler, D. Rodríguez, A. Prudova, and C.M. Overall Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome Mol. Cell. Proteom. MCP 7 2008 1925 1951 10.1074/mcp.R800012-MCP200
55. B. Turk Targeting proteases: successes, failures and future prospects Nat. Rev. Drug Discov. 5 2006 785 799 10.1038/nrd2092
56. A.P. Wiita, G.W. Hsu, C.M. Lu, J.H. Esensten, and J.A. Wells Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling Proc. Natl. Acad. Sci. U. S. A. 111 2014 7594 7599 10.1073/pnas.1405987111
57. G.A. McQuibban, J.H. Gong, E.M. Tam, C.A. McCulloch, I. Clark-Lewis, and C.M. Overall Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3 Science 289 2000 1202 1206
58. A.E. Starr, A. Dufour, J. Maier, and C.M. Overall Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16 J. Biol. Chem. 287 2012 5848 5860 10.1074/jbc.M111.314609
59. U. Repnik, A.E. Starr, C.M. Overall, and B. Turk Cysteine cathepsins activate ELR chemokines and inactivate non-ELR chemokines J. Biol. Chem. 290 2015 13800 13811 10.1074/jbc.M115.638395
60. N.N. Sluchanko, and N.B. Gusev Oligomeric structure of 14-3-3 protein: what do we know about monomers? FEBS Lett. 586 2012 4249 4256 10.1016/j.febslet.2012.10.048
61. V. Knäuper, H. Reinke, and H. Tschesche Inactivation of human plasma alpha 1-proteinase inhibitor by human PMN leucocyte collagenase FEBS Lett. 263 1990 355 357
62. S. Varland, C. Osberg, and T. Arnesen N-terminal modifications of cellular proteins: the enzymes involved, their substrate specificities and biological effects Proteomics 15 2015 2385 2401 10.1002/pmic.201400619
63. J.G. Tooley, and C.E. Schaner Tooley New roles for old modifications: emerging roles of N-terminal post-translational modifications in development and disease Protein Sci. Publ. Protein Soc. 23 2014 1641 1649 10.1002/pro.2547
64. T.V. Kalvik, and T. Arnesen Protein N-terminal acetyltransferases in cancer Oncogene 32 2013 269 276 10.1038/onc.2012.82
65. T. Farrah, E.W. Deutsch, G.S. Omenn, D.S. Campbell, Z. Sun, J.A. Bletz, and et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas Mol. Cell. Proteom. MCP 10 2011 10.1074/mcp.M110.006353 M110.006353
66. S. Hu, J.A. Loo, and D.T. Wong Human body fluid proteome analysis Proteomics 6 2006 6326 6353 10.1002/pmic.200600284
67. R.P. Fahlman, W. Chen, and C.M. Overall Absolute proteomic quantification of the activity state of proteases and proteolytic cleavages using proteolytic signature peptides and isobaric tags J. Proteom. 100 2014 79 91 10.1016/j.jprot.2013.09.006
68. P. Picotti, O. Rinner, R. Stallmach, F. Dautel, T. Farrah, B. Domon, and et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes Nat. Methods 7 2010 43 46 10.1038/nmeth.1408
69. O.T. Schubert, L.C. Gillet, B.C. Collins, P. Navarro, G. Rosenberger, W.E. Wolski, and et al. Building high-quality assay libraries for targeted analysis of SWATH MS data Nat. Protoc. 10 2015 426 441 10.1038/nprot.2015.015
70. S. Shao, T. Guo, C.C. Koh, S. Gillessen, M. Joerger, W. Jochum, and et al. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry Proteomics 2015 10.1002/pmic.201500161
71. E.C. Hayden Technology: The $1,000 genome Nature 507 2014 294 295 10.1038/507294a
72. E.R. Mardis The $1,000 genome, the $100,000 analysis? Genome Med. 2 2010 84 10.1186/gm205
73. M.I. McCarthy Genomics, type 2 diabetes, and obesity N. Engl. J. Med. 363 2010 2339 2350 10.1056/NEJMra0906948
74. L.-M.P. Britton, P. Sova, S. Belisle, S. Liu, E.Y. Chan, M.G. Katze, and et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection Proteomics 14 2014 2226 2230 10.1002/pmic.201400116
75. N.J. Schork Personalized medicine: time for one-person trials Nature 520 2015 609 611 10.1038/520609a
76. K.M. Giacomini, R.M. Krauss, D.M. Roden, M. Eichelbaum, M.R. Hayden, and Y. Nakamura When good drugs go bad Nature 446 2007 975 977 10.1038/446975a
77. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, and et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N. Engl. J. Med. 353 2005 1659 1672 10.1056/NEJMoa052306
78. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer, N.E. Davidson, and et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N. Engl. J. Med. 353 2005 1673 1684 10.1056/NEJMoa052122
79. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516 10.1056/NEJMoa1103782
80. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139 10.1056/NEJMoa040938
81. J.P. Higgins Smartphone applications for patients' health & fitness Am. J. Med. 2015 10.1016/j.amjmed.2015.05.038